Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Neoplasms of the CNS

Free Subscription Articles published in Acta Neuropathol Retrieve available abstracts of 73 articles: HTML format

Single Articles

March 2026
1. TAUZIEDE-ESPARIAT A, Castel D, Ajlil Y, Metais A, et al
   H3K27ME3 loss in diffuse midline gliomas lacking H3K27M or EZHIP expressions, a potential diagnostic pitfall!
   Acta Neuropathol. 2026;151:24.
   PubMed    
   
   
   
2. TLAIS D, Zhang Q, Roach JT, Tinkle CL, et al
   Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
   Acta Neuropathol. 2026;151:22.
   PubMed     Abstract available
   
   
   February 2026
3. FUJIMOTO K, Honda-Kitahara M, Hattori N, Matsushita Y, et al
   Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
   Acta Neuropathol. 2026;151:15.
   PubMed     Abstract available
   
   
   January 2026
4. BRAND F, Rose LS, Akbarzadeh AH, Weber CAM, et al
   Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
   Acta Neuropathol. 2026;151:6.
   PubMed     Abstract available
   
   
   November 2025
5. FURST A, Ruf V, Fiedler C, Rutkowski S, et al
   IDH mutations are rare events in SHH medulloblastoma.
   Acta Neuropathol. 2025;150:55.
   PubMed    
   
   
   October 2025
6. PFAFF E, Schramm K, Blattner-Johnson M, Jones BC, et al
   Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM.
   Acta Neuropathol. 2025;150:42.
   PubMed     Abstract available
   
   
   
7. LOTSCH C, Warta R, Liu F, Jungwirth G, et al
   Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells.
   Acta Neuropathol. 2025;150:41.
   PubMed     Abstract available
   
   
   September 2025
8. JURGENSEN L, Benfatto S, Schmid S, Daenekas B, et al
   In silico purification improves DNA methylation-based classification rates of pediatric low-grade gliomas.
   Acta Neuropathol. 2025;150:34.
   PubMed     Abstract available
   
   
   
9. ARTZI SB, Klausen MN, Harwood DSL, Michaelsen SR, et al
   Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma.
   Acta Neuropathol. 2025;150:29.
   PubMed     Abstract available
   
   
   
10. NANDAKUMAR S, Mehine M, Kemel Y, Bandlamudi C, et al
    Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.
    Acta Neuropathol. 2025;150:27.
    PubMed     Abstract available
    
    
    
11. COSTA FD, Alves de Castro JV, Gomes YM, Kulikowski LD, et al
    Pineal region high-grade neuroepithelial tumors with NTRK fusions map to the novel methylation class "diffuse high-grade glioma, IDH-wild type, subtype E".
    Acta Neuropathol. 2025;150:26.
    PubMed    
    
    
    August 2025
12. WEBER KJ, Dettki M, Munzberg M, Zeiner PS, et al
    DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.
    Acta Neuropathol. 2025;150:21.
    PubMed     Abstract available
    
    
    
13. MIKKELSEN MK, Li X, Yu K, High AA, et al
    Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis.
    Acta Neuropathol. 2025;150:18.
    PubMed     Abstract available
    
    
    
14. KECK MK, Al-Hussaini M, Amayiri N, Yiadom AAB, et al
    PLAG1 fusions define a third subtype of CNS embryonal tumor with PLAG family gene alteration.
    Acta Neuropathol. 2025;150:12.
    PubMed     Abstract available
    
    
    June 2025
15. COTTER JA, Markowitz AL, Castaneda E, Yen CY, et al
    CNS methylation classifiers may misclassify normal developing cerebellar cortex as medulloblastoma.
    Acta Neuropathol. 2025;149:66.
    PubMed    
    
    
    
16. KRECH M, Muench A, Teichmann D, Kuzman P, et al
    Outcome-associated factors in a molecularly defined cohort of central neurocytoma.
    Acta Neuropathol. 2025;149:61.
    PubMed     Abstract available
    
    
    April 2025
17. DWARSHUIS G, Kroon LL, Brandsma D, Noske DP, et al
    Liquid biopsies for the monitoring of gliomas and brain metastases in adults.
    Acta Neuropathol. 2025;149:37.
    PubMed     Abstract available
    
    
    
18. SINGH O, Dampier C, Abdullaev Z, Dazelle K, et al
    Diffuse astrocytoma, AYA-type, frequently MAPK-altered: report of 45 patients.
    Acta Neuropathol. 2025;149:32.
    PubMed     Abstract available
    
    
    March 2025
19. PURKAIT S, Praeger S, Felsberg J, Pauck D, et al
    Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma.
    Acta Neuropathol. 2025;149:29.
    PubMed     Abstract available
    
    
    February 2025
20. HINZ F, Friedel D, Korshunov A, Ippen FM, et al
    IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread.
    Acta Neuropathol. 2025;149:12.
    PubMed     Abstract available
    
    
    
21. FRIKER LL, Perwein T, Waha A, Dorner E, et al
    MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
    Acta Neuropathol. 2025;149:11.
    PubMed     Abstract available
    
    
    January 2025
22. PAGANI F, Orzan F, Lago S, De Bacco F, et al
    Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.
    Acta Neuropathol. 2025;149:8.
    PubMed     Abstract available
    
    
    
23. MADLENER S, Stepien N, Senfter D, Mayr L, et al
    Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method.
    Acta Neuropathol. 2025;149:5.
    PubMed     Abstract available
    
    
    November 2024
24. MIKOLAJEWICZ N, Tatari N, Wei J, Savage N, et al
    Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.
    Acta Neuropathol. 2024;148:74.
    PubMed     Abstract available
    
    
    
25. JOTANOVIC J, Boldt HB, Burton M, Andersen MS, et al
    Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.
    Acta Neuropathol. 2024;148:68.
    PubMed     Abstract available
    
    
    October 2024
26. CHUNG HJ, Rajan S, Wu Z, Ferrone CK, et al
    MYB/MYBL1-altered gliomas frequently harbor truncations and non-productive fusions in the MYB and MYBL1 genes.
    Acta Neuropathol. 2024;148:54.
    PubMed     Abstract available
    
    
    
27. GHISAI SA, van Hijfte L, Vallentgoed WR, Tesileanu CMS, et al
    Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
    Acta Neuropathol. 2024;148:50.
    PubMed     Abstract available
    
    
    September 2024
28. NUECHTERLEIN N, Cimino S, Shelbourn A, Ha V, et al
    HOXD12 defines an age-related aggressive subtype of oligodendroglioma.
    Acta Neuropathol. 2024;148:41.
    PubMed     Abstract available
    
    
    
29. STEGAT L, Eckhardt A, Gocke A, Neyazi S, et al
    Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.
    Acta Neuropathol. 2024;148:40.
    PubMed     Abstract available
    
    
    
30. SOL N, Kooi EJ, Pages-Gallego M, Brandsma D, et al
    Glioblastoma, IDH-wildtype with primarily leptomeningeal localization diagnosed by nanopore sequencing of cell-free DNA from cerebrospinal fluid.
    Acta Neuropathol. 2024;148:35.
    PubMed    
    
    
    
31. HENCH J, Hultschig C, Bratic Hench I, Sadasivan H, et al
    Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid.
    Acta Neuropathol. 2024;148:36.
    PubMed    
    
    
    August 2024
32. TERANISHI Y, Yurchenko A, Tran S, Sievers P, et al
    Correlation between natural history and multi-omics profiling of meningiomas in NF2-related schwannomatosis suggests role of methylation group and immune microenvironment in tumor growth rate.
    Acta Neuropathol. 2024;148:30.
    PubMed    
    
    
    
33. AN S, McCortney K, Walshon J, Leonard K, et al
    Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients.
    Acta Neuropathol. 2024;148:29.
    PubMed    
    
    
    
34. LECLAIR NK, Lucas CG, Mirchia K, McCortney K, et al
    The RNA-binding protein IGF2BP1 regulates stability of mRNA transcribed from FOXM1 target genes in hypermitotic meningiomas.
    Acta Neuropathol. 2024;148:28.
    PubMed    
    
    
    
35. LE QUANG M, Trinquet A, Siegfried A, de Barros A, et al
    FGFR1 wild-type rosette-forming glioneuronal tumours.
    Acta Neuropathol. 2024;148:26.
    PubMed    
    
    
    
36. ZHANG KY, Parker M, Weber-Levine C, Kalluri A, et al
    ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.
    Acta Neuropathol. 2024;148:19.
    PubMed    
    
    
    
37. MAAS SLN, Hielscher T, Sievers P, Hovestadt V, et al
    Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma.
    Acta Neuropathol. 2024;148:17.
    PubMed    
    
    
    July 2024
38. PRIESTERBACH-ACKLEY LP, Cordier F, de Witt Hamer P, Snijders TJ, et al
    Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4.
    Acta Neuropathol. 2024;148:12.
    PubMed    
    
    
    
39. SIEVERS P, Bielle F, Gobel K, Schrimpf D, et al
    Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations.
    Acta Neuropathol. 2024;148:7.
    PubMed    
    
    
    
40. RICHARDSON TE, Walker JM, Hambardzumyan D, Brem S, et al
    Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
    Acta Neuropathol. 2024;148:5.
    PubMed     Abstract available
    
    
    June 2024
41. OKONECHNIKOV K, Schrimpf D, Koster J, Sievers P, et al
    Clinically unfavorable transcriptome subtypes of non-WNT/non-SHH medulloblastomas are associated with a predominance in proliferating and progenitor-like cell subpopulations.
    Acta Neuropathol. 2024;147:95.
    PubMed     Abstract available
    
    
    May 2024
42. LIN AL, Rudneva VA, Richards AL, Zhang Y, et al
    Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Acta Neuropathol. 2024;147:85.
    PubMed     Abstract available
    
    
    
43. SCHULLER U, Gocke A, Godbole S, Delbridge C, et al
    Anaplastic histology and distinct molecular features in a small series of spinal cord ependymomas.
    Acta Neuropathol. 2024;147:83.
    PubMed    
    
    
    April 2024
44. NASSIRI F, Ajisebutu A, Patil V, Mamatjan Y, et al
    Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
    Acta Neuropathol. 2024;147:68.
    PubMed     Abstract available
    
    
    March 2024
45. REDMER T, Schumann E, Peters K, Weidemeier ME, et al
    Correction to: MET receptor serves as a promising target in melanoma brain metastases.
    Acta Neuropathol. 2024;147:63.
    PubMed    
    
    
    
46. ZAKIMI N, Nguyen MP, Raleigh DR
    Gene transcript fusions are associated with clinical outcomes and molecular groups of meningiomas.
    Acta Neuropathol. 2024;147:57.
    PubMed    
    
    
    February 2024
47. REDMER T, Schumann E, Peters K, Weidemeier ME, et al
    MET receptor serves as a promising target in melanoma brain metastases.
    Acta Neuropathol. 2024;147:44.
    PubMed     Abstract available
    
    
    
48. HARMANCI AS, Boudreau B, Lau S, Hosseingholi Nouri S, et al
    Aggressive human MenG C meningiomas have a molecular counterpart in canines.
    Acta Neuropathol. 2024;147:42.
    PubMed    
    
    
    
49. ZAKIMI N, Mazcko CN, Toedebusch C, Tawa G, et al
    Canine meningiomas are comprised of 3 DNA methylation groups that resemble the molecular characteristics of human meningiomas.
    Acta Neuropathol. 2024;147:43.
    PubMed    
    
    
    
50. RAHMANZADE R, Sahm F
    Reply: pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusion.
    Acta Neuropathol. 2024;147:35.
    PubMed    
    
    
    
51. VASILJEVIC A
    Pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusion. Scientific commentary on 'Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate diffe
    Acta Neuropathol. 2024;147:34.
    PubMed    
    
    
    January 2024
52. NEYAZI S, Yamazawa E, Hack K, Tanaka S, et al
    Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
    Acta Neuropathol. 2024;147:22.
    PubMed     Abstract available
    
    
    
53. DREXLER R, Khatri R, Schuller U, Eckhardt A, et al
    Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma.
    Acta Neuropathol. 2024;147:21.
    PubMed     Abstract available
    
    
    
54. DOTTERMUSCH M, Ryba A, Ricklefs FL, Flitsch J, et al
    Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Acta Neuropathol. 2024;147:16.
    PubMed     Abstract available
    
    
    December 2023
55. HADAD S, Gupta R, Oberheim Bush NA, Taylor JW, et al
    "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Acta Neuropathol. 2023;147:3.
    PubMed     Abstract available
    
    
    
56. AUFFRET L, Ajlil Y, Tauziede-Espariat A, Kergrohen T, et al
    A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Acta Neuropathol. 2023;147:2.
    PubMed     Abstract available
    
    
    
57. HICKMAN RA, Gedvilaite E, Ptashkin R, Reiner AS, et al
    CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
    Acta Neuropathol. 2023;146:845-847.
    PubMed    
    
    
    
58. RAHMANZADE R, Pfaff E, Banan R, Sievers P, et al
    Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics.
    Acta Neuropathol. 2023;146:853-856.
    PubMed    
    
    
    October 2023
59. MAAS SLN, Sievers P, Weber DC, Weller M, et al
    Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042.
    Acta Neuropathol. 2023 Oct 19. doi: 10.1007/s00401-023-02642.
    PubMed    
    
    
    
60. ROBERTS HJ, Ji S, Picca A, Sanson M, et al
    Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
    Acta Neuropathol. 2023 Oct 18. doi: 10.1007/s00401-023-02640.
    PubMed    
    
    
    
61. PICARD D, Felsberg J, Langini M, Stachura P, et al
    Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma.
    Acta Neuropathol. 2023;146:551-564.
    PubMed     Abstract available
    
    
    September 2023
62. BOETTO J, Plu I, Ducos Y, Blouin A, et al
    Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes.
    Acta Neuropathol. 2023 Sep 26. doi: 10.1007/s00401-023-02635.
    PubMed    
    
    
    
63. TRAN QT, Upadhyaya SA, Billups CA, Onar-Thomas A, et al
    DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts.
    Acta Neuropathol. 2023;146:543-545.
    PubMed    
    
    
    
64. JOHANN PD, Altendorf L, Efremova EM, Holsten T, et al
    Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics.
    Acta Neuropathol. 2023;146:527-541.
    PubMed     Abstract available
    
    
    August 2023
65. WIRSCHING HG, Felsberg J, Prummer M, Moisoiu V, et al
    Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.
    Acta Neuropathol. 2023 Aug 13. doi: 10.1007/s00401-023-02617.
    PubMed    
    
    
    July 2023
66. WILLIAMS EA, Brastianos PK, Wakimoto H, Zolal A, et al
    A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Acta Neuropathol. 2023 Jul 31. doi: 10.1007/s00401-023-02609.
    PubMed     Abstract available
    
    
    June 2023
67. MEDICI G, Freudenmann LK, Velz J, Wang SS, et al
    A T-cell antigen atlas for meningioma: novel options for immunotherapy.
    Acta Neuropathol. 2023 Jun 27. doi: 10.1007/s00401-023-02605.
    PubMed     Abstract available
    
    
    
68. MADLENER S, Furtner J, Stepien N, Senfter D, et al
    Clinical applicability of miR517a detection in liquid biopsies of ETMR patients.
    Acta Neuropathol. 2023;145:843-846.
    PubMed    
    
    
    May 2023
69. WANG JZ, Patil V, Liu J, Dogan H, et al
    Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 May 12. doi: 10.1007/s00401-023-02584.
    PubMed    
    
    
    April 2023
70. KORSHUNOV A, Okonechnikov K, Schrimpf D, Tonn S, et al
    Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02575.
    PubMed     Abstract available
    
    
    
71. WANG JZ, Patil V, Liu J, Dogan H, et al
    Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02571.
    PubMed     Abstract available
    
    
    
72. GODDARD J, Castle J, Southworth E, Fletcher A, et al
    Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
    Acta Neuropathol. 2023 Apr 4. doi: 10.1007/s00401-023-02566.
    PubMed     Abstract available
    
    
    March 2023
73. BOGUMIL H, Sill M, Schrimpf D, Ismer B, et al
    Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
    Acta Neuropathol. 2023 Mar 18. doi: 10.1007/s00401-023-02558.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum